Bioreductive drugs into the next millennium

Anti-Cancer Drug Design

Volumn 13, Issue 6, 1998, Pages 519-528

  Stratford, Ian J ^a   Workman, Paul ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; MITOMYCIN C;

ANTINEOPLASTIC ACTIVITY; CELL HYPOXIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; PRIORITY JOURNAL; REVIEW; TISSUE OXYGENATION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DRUG DESIGN; HUMANS; OXIDATION-REDUCTION;

EID: 0031661074     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. ABOAGYE, E.O , KELSON, A.B., TRACY, M & WORKMAN, P (1998). Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl)acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumour hypoxia by magnetic resonance spectroscopy and imaging and by positron emission tomography. Anti-Cancer Drug Design, 13, 703.
2. BRIZEL, D.M., SCULLY, S.P., HARRELSON, J.M., LAYFIELD, L.J., BEAN, J.M., PROSNITZ, L.R. & DEWHIRST, M.W. (1996). Tumour oxygenation predicts the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research, 56, 941.
3. BROWN, JM. (1993). SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. British Journal of Cancer, 67, 1163.
4. BROWN, J.M. & WANG, L.H. (1998). Tirapazamine: laboratory data relevant to clinical activity. Anti-Cancer Drug Design, 13, 529.
5. CHAPMAN, J.D., LEE, J & MEEKER, B.E. (1990). Adduct formation by 2-nitroimidazole drugs in mammalian cells: optimization of markers for tissue organization. In Selective Activation of Drugs by Redox Processes. Adams, G.E., Breccia, A., Fielden, E.M. & Wardman, P. (eds), p. 313. Plenum Press: New York.
6. DACHS, G.U. & STRATFORD, I.J (1996). The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. British Journal of Cancer, 74 (Suppl. XXVII), S126.
7. DACHS, G.U., PATTERSON, A.V., FIRTH, J.D., RATCLIFFE, P J , STUART TOWNSEND, K.M., STRATFORD, I.J. & HARRIS, A.L. (1997). Targetting gene expression to hypoxic tumour cells. Nature, Medicine, 3, 515.
8. DENNY, W.A , WILSON, W.R. & HAY, M P (1996). Recent developments in the design of bioreductive drugs. British Journal of Cancer, 74 (Suppl. XXVII), S32.
9. EVANS, J.E , YUDOH, K., DELAHOUSSAYE, Y.M. & BROWN, J.M. (1998). Tirapazamine is metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Research, 58, 2098.
10. FITZSIMMONS, S.A , LEWIS, A.D , RILEY, R J. & WORKMAN, P. (1994). Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine; WIN 59075; SR 4233) to a DNA-damaging species: a direct role for NADPH: cytochrome P450 reductase. Carcinogenesis, 15, 1503.
11. FITZSIMMONS, S.A., WORKMAN, P, GREVER, M., PAULL, K , CARNELIER, R. & LEWIS, A.D (1996). Reductase expression across the National Cancer Institute tumour cell line panel: correlation with sensitivity to mitomycin C and EO9. Journal of the National Cancer Institute, 88, 259.
12. GATENBY, R.A., KESSLER, H.B., ROSENBLUM, J.S., BOIA, L.R , MOLDOFSKY, P.J., HARTZ, W.H. & BRODER, G.J. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. International Journal of Radiation Oncology Biology Physics, 14, 831.
13. GRAEBER, T.G., OSMANINAN, C , JACKS, T., HOUSMAN, D.E., KOCH, C K., LOWE, S.W & GIACIA, A J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379, 88.
14. HAFFTY, B.G., SON, Y.H., SASAKI, C.T, PAPAC, R., FISCHER, D., ROCKWELL, S., SARTORELLI, A. & FISCHER, J.J. (1993). Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomised clinical trials. International Journal of Radiation Oncology Biology Physics, 27, 241.
15. 2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology, 26, 45.
16. HOCKEL, M , SCHLENGER, K., MITZE, M , SCHAFFER, U & VAUPEL, P (1996a). Hypoxia and radiation response in human tumours. Seminars in Radiation Oncology, 6, 3.
17. HÖCKEL, M , SCHLENGER, K., ARAL, B., MITZE, M., SCHAFFER, U & VAUPEL, P. (1996b). Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research, 56, 4509.
18. HODGKISS, R.J. (1998). Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anti-Cancer Drug Design, 13, 687.
19. JAFFAR, M., NAYLOR, MA, ROBERTSON, N., LOCKYER, S D , PHILLIPS, R.M., EVERETT, S.A , ADAMS, G.E. & STRATFORD, I.J. (1998). 5-Substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2[1H-indole-4,7-dione]prop-2-en-1-o1 (EO9) and their regio isomers as hypoxia-selective agents: structure - cytotoxicity in vitro. Anti-Cancer Drug Design, 13, 105.
20. JAIN, R.K. (1998). The next frontier of molecular medicine: delivery of therapeutics. Nature, Medicine, 4, 655.
21. KOCH, C J (1993). Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Research, 53, 3992.
22. LEE, D.J., TROTTI, A.S.S , ROSTOCK, R., FISHER, C., VON ROEMELING, R., HARVEY, E & GROVES, E. (1998). A phase II trial of radiotherapy with concurrent tirapazamine, a hypoxic cytotoxin, for advanced head and neck carcinomas. International Journal of Radiation Oncology Biology Physics, in press.
23. MARSHALL, R.S. & RAUTH, A M (1988). Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Research, 48, 2709.
24. MOHINDRA, J.K. & RAUTH, A.M (1976). Increeased cell killing by metronidazole andnitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Research, 36, 930.
25. NICULESCU-DUVAZ, I. & SPRINGER, C.J (1997). Gene-directed enzyme prodrug therapy: a review of enzyme prodrug combinations. Expert Opinion in Investigational Drugs, 6, 685.
26. NORDSMARK, M., OVERGAARD, M. & OVERGAARD, J. (1996). Pre-treatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 41, 31.
27. OVERGAARD, J. & HORSMAN, M.R. (1996). Modification of hypoxia-induced radioresistance in tumours by the use of oxygen and sensitizers. Seminars in Radiation Oncology, 6, 10.
28. PATTERSON, A.V., BARHAM, H.M , CHINJE, E C , ADAMS, G.E , HARRIS, A.L & STRATFORD, I.J. (1995). Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). British Journal of Cancer, 72, 1144.
29. PATTERSON, A.V., SAUNDERS, M.P., CHINJE, E.C., TALBOT, D.C., HARRIS, A.L. & STRATFORD, I J. (1997). Overexpression of human NADPH: cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233). and RSU 1069. British Journal of Cancer, 76, 1338.
30. PATTERSON, A.V., SAUNDERS, M.P., CHINJE, E.C , PATTERSON, L.H. & STRATFORD, I J (1998). Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Design, 13, 541.
31. PLATE, L J, BREOER, G., WEOCJ, J.A. & ROSAI, W. (1992). Vascular endothelial growth-factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845.
32. PLUMB, J.A. & WORKMAN, P. (1994). Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. International Journal of Cancer, 56, 134.
33. RALEIGH, J.A., DEWHIRST, M.W. & THRALL, D.E. (1996). Measuring tumour hypoxia. Seminars in Radiation Oncology, 6, 37.
34. 2 distribution and bioreductive enzymes in human malignant brain tumours. International Journal of Radiation Oncology Biology Physics, 29, 427.
35. ROBERTSON, N , HAIGH, A., ADAMS, G.E. & STRATFORD, I.J. (1994). Factors affecting sensiivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase4 activity and hypoxia. European Journal of Cancer, 30A, 1013.
36. ROBERTSON, N., STRATFORD, I.J., HOULBROOK, S., CARMICHAEL, J & ADAMS, G.E. (1992). The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochemical Pharmacology, 44, 409.
37. SHWEIKI, D , ITIN, A., SOFFER, D & KESHET, E (1992). Vascular endothelial growth-factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, 843.
38. SHWEIKI, D., NEEMAN, M., ITIN, A. & KESHET, E. (1995). Induction of vascular endothelial growth-factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proceedings of the National Academy of Sciences, USA, 92, 768.
39. TAYLOR, Y.C. & RAUTH, A.M (1980). Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro. British Journal of Cancer, 41, 892.
40. VAUPEL, P , KALLINOWSKI, F. & OKUNIEFF, P. (1989). Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumours: a review. Cancer Research, 49, 6449.
41. VON PAWEL, J. & VON ROEMELING, R (1998). Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT 1 trial. Proceedings of the American Society for Clinical Oncology, 17, 454a (Abstr. 1749).
42. WALTON, M.I. & WORKMAN, p (1987). Nitroimidazole bioreductive metabolism: quantitation and characterisation of mouse tissue benzonidazole nitroreductase in vivo and in vitro. Biochemical Pharmacology, 36, 887.
43. WALTON, M.I. & WORKMAN, P (1990). Enzymology of the reductive bioactivation of SR 4233: a novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochemical Pharmacology, 39, 1735.
44. WALTON, M.I , SMITH, P.J. & WORKMAN, P. (1991). The role of NAD(P)H:quinone reductase (EC1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9. Cancer Communications, 3, 199.
45. WALTON, M I., WOLF, C R & WORKMAN, P. (1992). The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochemical Pharmacology, 44, 251.
46. WARDMAN, P. (1998). The chemistry of nitroarene and aromatic N-oxide radicals. In The Chemistry of N-Centred Radicals. Alfassi, Z.B. (ed.), John Wiley: New York, in press.
47. WEIDNER, N., SEMPLE, J P, WELCH, W.R. & FOLKMAN, J. (1991). Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. New England Journal of Medicine, 324, 1.
48. WORKMAN, P (1994). Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncology Research, 6, 461.
49. WORKMAN, P & WALTON, M I (1990). Enyme-directed bioreductive drug development. In Selective Activation of Drugs by Redox Processes. Adams, G.E., Breccia, A., Fielden, E.M. & Wardman, P. (eds), p. 173. Plenum Press: New York.
50. WORKMAN, P & STRATFORD, I J. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Reviews, 12, 73.
51. YOUNG, S.D , MARSHALL, R S & HILL, R.P. (1988). Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumour cells. Proceedings of the National Academy of Sciences, USA, 85, 9533.